Meridian Bioscience (VIVO) Declares $0.20 Quarterly Dividend; 4.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Canaccord Genuity Cuts Price Target on Meridian Bioscience (VIVO) Following In-Line Quarter Results
July 27, 2015 9:18 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and cut the price target to $19.00 (from $20.00), following quarterly results. Revenues of $48.3M narrowly missed the Street's $48.6M. EPS of $0.22 was in line with the Street.
Analyst Mark Massaro... More
Meridian Bioscience (VIVO) Reports In-Line Q2 EPS
July 23, 2015 8:26 AM EDTMeridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.22, in-line with the analyst estimate of $0.22. Revenue for the quarter came in at $48.2 million versus the consensus estimate of $48.6 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
... More